The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression

Journal of Biological Chemistry

Volumn 287, Issue 29, 2012, Pages 24631-24640

  Sizemore, Steven T ^a   Keri, Ruth A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST CANCER CELLS; CELL LINES; CO-EXPRESSION; INDEPENDENT PREDICTORS; INVASIVENESS; MAMMARY EPITHELIAL CELLS; MATRIX METALLOPROTEASE; MATRIX METALLOPROTEINASES; MOLECULAR TARGETS; MULTI VARIATE ANALYSIS; PROTEIN LEVEL; THERAPEUTIC TARGETS; TRANSIENT EXPRESSION;

CELL CULTURE; CELLS; TRANSCRIPTION FACTORS;

DISEASES;

MATRILYSIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; TRANSCRIPTION FACTOR FOXC1;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER INVASION; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ANALYSIS; ENZYME INDUCTION; EPITHELIUM CELL; FOXC1 GENE; GENE; GENE EXPRESSION; METASTASIS; MMP7 GENE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MATRIX METALLOPROTEINASE 7; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84863791651     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.375865     Document Type: Article

References (44)

1. Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., and Boyle, P. (2003) Overview of the main outcomes in breast cancer prevention trials. Lancet 361, 296-300 (Pubitemid 36126189)
2. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer. An overview of the randomised trials. Lancet 351, 1451-1467
3. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., and Slamon, D. J. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659-2671 (Pubitemid 28363029)
4. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (Pubitemid 32222155)
5. Gucalp, A., and Traina, T. A. (2011) Triple negative breast cancer. Adjuvant therapeutic options. Chemother. Res. Pract. 696208
6. Pal, S. K., Childs, B. H., and Pegram, M. (2011) Triple negative breast cancer. Unmet medical needs. Breast Cancer Res. Treat. 125, 627-636
7. Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., and Birnbaum, D. (2008) How basal are triple negative breast cancers? Int. J. Cancer 123, 236-240 (Pubitemid 351705215)
8. Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., and Narod, S. A. (2007) Triple negative breast cancer. Clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434 (Pubitemid 47219710)
9. Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., and Clemons, M. (2009) Survival outcomes for patients with metastatic triple negative breast cancer. Implications for clinical practice and trial design. Clin. Breast Cancer 9, 29-33
10. Hicks, D. G., Short, S. M., Prescott, N. L., Tarr, S. M., Coleman, K. A., Yoder, B. J., Crowe, J. P., Choueiri, T. K., Dawson, A. E., Budd, G. T., Tubbs, R. R., Casey, G., and Weil, R. J. (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am. J. Surg. Pathol. 30, 1097-1104 (Pubitemid 44299342)
11. Myatt, S. S., and Lam, E. W. (2007) The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 7, 847-859 (Pubitemid 350006253)
12. Kidson, S. H., Kume, T., Deng, K., Winfrey, V., and Hogan, B. L. (1999) The forkhead/winged-helix gene, Mf1, is necessary for the normal development of the cornea and formation of the anterior chamber in the mouse eye. Dev. Biol. 211, 306-322 (Pubitemid 29343284)
13. Kume, T., Deng, K. Y., Winfrey, V., Gould, D. B., Walter, M. A., and Hogan, B. L. (1998) The forkhead/winged helix gene Mf1 is disrupted in the pleiotropic mouse mutation congenital hydrocephalus. Cell 93, 985-996 (Pubitemid 28280792)
14. Mears, A. J., Jordan, T., Mirzayans, F., Dubois, S., Kume, T., Parlee, M., Ritch, R., Koop, B., Kuo, W. L., Collins, C., Marshall, J., Gould, D. B., Pearce, W., Carlsson, P., Enerbäck, S., Morissette, J., Bhattacharya, S., Hogan, B., Raymond, V., and Walter, M. A. (1998) Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly. Am. J. Hum. Genet. 63, 1316-1328 (Pubitemid 30418529)
15. Du, J., Li, L., Ou, Z., Kong, C., Zhang, Y., Dong, Z., Zhu, S., Jiang, H., Shao, Z., Huang, B., and Lu, J. (2012) FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res. Treat. 131, 65-73
16. Chung, T. K., Lau, T. S., Cheung, T. H., Yim, S. F., Lo, K. W., Siu, N. S., Chan, L. K., Yu, M. Y., Kwong, J., Doran, G., Barroilhet, L. M., Ng, A. S., Wong, R. R., Wang, V. W., Mok, S. C., Smith, D. I., Berkowitz, R. S., and Wong, Y. F. (2012) Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int. J. Cancer 130, 1036-1045
17. Ray, P. S., Wang, J., Qu, Y., Sim, M. S., Shamonki, J., Bagaria, S. P., Ye, X., Liu, B., Elashoff, D., Hoon, D. S., Walter, M. A., Martens, J. W., Richardson, A. L., Giuliano, A. E., and Cui, X. (2010) FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 70, 3870-3876
18. Bloushtain-Qimron, N., Yao, J., Snyder, E. L., Shipitsin, M., Campbell, L. L., Mani, S. A., Hu, M., Chen, H., Ustyansky, V., Antosiewicz, J. E., Argani, P., Halushka, M. K., Thomson, J. A., Pharoah, P., Porgador, A., Sukumar, S., Parsons, R., Richardson, A. L., Stampfer, M. R., Gelman, R. S., Nikolskaya, T., Nikolsky, Y., and Polyak, K. (2008) Cell type-specific DNA methylation patterns in the human breast. Proc. Natl. Acad. Sci. U.S.A. 105, 14076-14081
19. Wang, J., Ray, P. S., Sim, M. S., Zhou, X. Z., Lu, K. P., Lee, A. V., Lin, X., Bagaria, S. P., Giuliano, A. E., and Cui, X. (2012) FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling. Oncogene, in press
20. Ray, P. S., Bagaria, S. P., Wang, J., Shamonki, J. M., Ye, X., Sim, M. S., Steen, S., Qu, Y., Cui, X., and Giuliano, A. E. (2011) Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value. A retrospective immunohistochemical study. Ann. Surg. Oncol. 18, 3839-3847
21. Taube, J. H., Herschkowitz, J. I., Komurov, K., Zhou, A. Y., Gupta, S., Yang, J., Hartwell, K., Onder, T. T., Gupta, P. B., Evans, K. W., Hollier, B. G., Ram, P. T., Lander, E. S., Rosen, J. M., Weinberg, R. A., and Mani, S. A. (2010) Core epithelial-to-mesenchymal transition interactome gene expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. U.S.A. 107, 15449-15454
22. Sizemore, S., Cicek, M., Sizemore, N., Ng, K. P., and Casey, G. (2007) Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res. 67, 6183-6191 (Pubitemid 47037499)
23. Fernández-Resa, P., Mira, E., and Quesada, A. R. (1995) Enhanced detection of casein zymography of matrix metalloproteinases. Anal. Biochem. 224, 434-435
24. Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, D., Lønning, P. E., and Børresen-Dale, A. L. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98, 10869-10874
25. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E. T., Friend, S. H., and Bernards, R. (2002) A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (Pubitemid 35461656)
26. Jacobsen, L., Calvin, S., and Lobenhofer, E. (2009) Transcriptional effects of transfection. The potential for misinterpretation of gene expression data generated from transiently transfected cells. BioTechniques 47, 617-624
27. Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J. P., Tong, F., Speed, T., Spellman, P. T., DeVries, S., Lapuk, A., Wang, N. J., Kuo, W. L., Stilwell, J. L., Pinkel, D., Albertson, D. G., Waldman, F. M., McCormick, F., Dickson, R. B., Johnson, M. D., Lippman, M., Ethier, S., Gazdar, A., and Gray, J. W. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (Pubitemid 44854747)
28. Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adélaïde, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., Birnbaum, D., and Bertucci, F. (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25, 2273-2284
29. Tkocz, D., Crawford, N. T., Buckley, N. E., Berry, F. B., Kennedy, R. D., Gorski, J. J., Harkin, D. P., and Mullan, P. B. (2011) BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene, in press
30. Berry, F. B., Skarie, J. M., Mirzayans, F., Fortin, Y., Hudson, T. J., Raymond, V., Link, B. A., and Walter, M. A. (2008) FOXC1 is required for cell viability and resistance to oxidative stress in the eye through the transcriptional regulation of FOXO1A. Hum. Mol. Genet. 17, 490-505 (Pubitemid 351201765)
31. Matrisian, L. M., Wright, J., Newell, K., and Witty, J. P. (1994) Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp. 24, 152-161
32. Powell, W. C., Knox, J. D., Navre, M., Grogan, T. M., Kittelson, J., Nagle, R. B., and Bowden, G. T. (1993) Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res. 53, 417-422 (Pubitemid 23031858)
33. Witty, J. P., McDonnell, S., Newell, K. J., Cannon, P., Navre, M., Tressler, R. J., and Matrisian, L. M. (1994) Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 54, 4805-4812 (Pubitemid 24276516)
34. Yamamoto, H., Itoh, F., Hinoda, Y., and Imai, K. (1995) Suppression of matrilysin inhibits colon cancer cell invasion in vitro. Int. J. Cancer 61, 218-222
35. Fukushima, H., Yamamoto, H., Itoh, F., Nakamura, H., Min, Y., Horiuchi, S., Iku, S., Sasaki, S., and Imai, K. (2001) Association of matrilysin mRNA expression with K-ras mutations and progression in pancreatic ductal adenocarcinomas. Carcinogenesis 22, 1049-1052 (Pubitemid 32633603)
36. Nakamura, H., Horita, S., Senmaru, N., Miyasaka, Y., Gohda, T., Inoue, Y., Fujita, M., Meguro, T., Morita, T., and Nagashima, K. (2002) Association of matrilysin expression with progression and poor prognosis in human pancreatic adenocarcinoma. Oncol. Rep. 9, 751-755
37. Wang, W. S., Chen, P. M., Wang, H. S., Liang, W. Y., and Su, Y. (2006) Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 27, 1113-1120
38. Jiang, W. G., Davies, G., Martin, T. A., Parr, C., Watkins, G., Mason, M. D., Mokbel, K., and Mansel, R. E. (2005) Targeting matrilysin and its impact on tumor growth I. The potential implications in breast cancer therapy. Clin. Cancer Res. 11, 6012-6019 (Pubitemid 41170333)
39. Lynch, C. C., Vargo-Gogola, T., Martin, M. D., Fingleton, B., Crawford, H. C., and Matrisian, L. M. (2007) Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor. Cancer Res. 67, 6760-6767 (Pubitemid 47105523)
40. Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., and Perou, C. M. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68
41. Prat, A., and Perou, C. M. (2011) Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5, 5-23
42. Sato, N., Maehara, N., Su, G. H., and Goggins, M. (2003) Effects of 5-aza- 2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J. Natl. Cancer Inst. 95, 327-330
43. Debnath, J., and Brugge, J. S. (2005) Modeling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 5, 675-688 (Pubitemid 41486361)
44. Richards, T., Park, C., Chen, Y., Gibson, K. F., Di, Y. P., Pardo, A., Watkins, S. C., Choi, A. M., Selman, M., Pilewski, J. M., Kaminski, N., and Zhang, Y. (2012) Allele-specific transactivation of matrix metalloproteinase 7 by FOXA2 and correlation with plasma levels in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 302, L746-L754